Zacks Investment Research
26 Aug 2026, 14:55 UTC · 10w ago
Impact · against what's priced in
The stock shows positive momentum based on aggressive analyst price targets and upward earnings revisions. With a mean target of $156.60 and a current price of $79.49, there is a significant gap between market valuation and analyst expectations.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish
Wall Street analysts have a mean short-term price target of $156.60 for Bright Minds Biosciences Inc. (DRUG), representing a potential upside of 97% from its current price of $79.49.
So whatA high consensus price target relative to current trading price typically attracts bullish sentiment and speculative buying.
More positive than 92% of claims this week
Analysts are revising their earnings estimates for Bright Minds Biosciences Inc. upward, indicating expectations for better-than-previously-estimated performance.
Continue reading
5 related stories
Wall Street analysts have a mean price target of $156.60, suggesting a 97% upside from the current $79.49 price, supported by upward earnings revisions.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company has seen recent price gains and has a highly positive consensus analyst price target with upward earnings revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
4h ago
−74.3%
Price is moving against the score
$20.41 vs $79.49 close before publication (Aug 25) · not market-adjusted
DRUG chart →
